# US Retinal Drugs Market > US Retinal Drugs Market Research Report By Distribution Channel (Hospital pharmacy, Retail pharmacy, Online Pharmacy) and By Indication (Macular degeneration, Diabetic eye disease, Others) - Growth & Industry Forecast 2025 To 2035 - **Forecast Period:** 2025 - 2035 - **CAGR:** 6.3% - **2024:** $ 1,402.65 Million - **2025:** $ 1,491.02 Million - **2035:** $ 2,747.29 Million - **Key Players:** Regeneron Pharmaceuticals (US), Novartis (CH), Roche (CH), Bayer (DE), Pfizer (US), Santen Pharmaceutical (JP), Horizon Therapeutics (IE), Apellis Pharmaceuticals (US), Alimera Sciences (US) **Report ID:** MRFR/Pharma/18165-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Garvit Vyas · **Last Updated:** April 06, 2026 **URL:** https://www.marketresearchfuture.com/reports/us-retinal-drugs-market-19712 --- ## Market Summary ## **US Retinal Drugs Market Overview** As per MRFR analysis, the US Retinal Drugs Market Size was estimated at 1.22 (USD Billion) in 2023. The US Retinal Drugs Market Industry is expected to grow from 1.3(USD Billion) in 2024 to 2.54 (USD Billion) by 2035. The US Retinal Drugs Market CAGR (growth rate) is expected to be around 6.295% during the forecast period (2025 - 2035). ### **Key US Retinal Drugs Market Trends Highlighted** The US Retinal Drugs Market is experiencing significant trends influenced by the growing prevalence of retinal disorders, which affects millions of Americans. Increased awareness about eye health and advancements in diagnostic techniques are driving demand for innovative treatments. With conditions like age-related macular degeneration and diabetic retinopathy becoming more common, healthcare providers are focusing on newer therapeutic solutions. The rise in the aging population is a key market driver, as older adults are more susceptible to these diseases. Additionally, increased funding for research and development has led to a surge in the pipeline of retinal drugs, presenting numerous opportunities for manufacturers and researchers to explore. Recent trends indicate a shift toward personalized medicine, with therapies being tailored to individual patient profiles for better outcomes. Moreover, emerging biologics and gene therapies show promise, allowing for more effective treatments for previously difficult conditions. The advent of telemedicine has also transformed patient access to care, enabling timely consultations and improving the management of retinal diseases. Another notable trend is the integration of technology in drug delivery systems, such as sustained-release implants, which enhance patient compliance and treatment efficacy. Overall, the US [Retinal Drugs Market](../../../reports/retinal-drugs-market-11735) presents ample opportunities to develop innovative treatments, leveraging advances in science and technology. This growth environment paves the way for both established companies and new entrants to capitalize on the changing landscape of retinal care, ensuring that patients receive improved therapeutic options for their eye health. Collaborations between research institutions and pharmaceutical companies are expected to further drive this market, emphasizing the importance of strategic partnerships in addressing unmet medical needs in the field of retinal health. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ## **US Retinal Drugs Market Drivers** ### **Growing Incidence of Age-Related Macular Degeneration** Age-Related Macular Degeneration (AMD) is one of the leading causes of vision loss among older adults in the United States. According to the National Eye Institute, by 2050, the number of Americans with AMD is expected to reach nearly 3 million, a significant increase from 2.07 million reported in 2015. This growing aging population is showing a drastic need for effective retinal drugs, driving expansion in the US Retinal Drugs Market Industry. Moreover, major pharmaceutical companies like Regeneron Pharmaceuticals and Novartis are actively involved in developing and marketing treatments for AMD, such as EYLEA and Lucentis, contributing to advancements in therapeutic options. These factors amplify the demand for innovative retinal drugs, underpinning market growth. ### **Technological Advancements in Drug Development** Advancements in Biotechnology and Research and Development (R&D) are significantly impacting the US Retinal Drugs Market Industry. Innovative technologies such as gene therapy and biologics have transformed treatment paradigms for conditions like diabetic retinopathy and retinitis pigmentosa. For instance, the FDA has approved several gene therapies including Luxturna, aiming to tackle inherited retinal diseases. Establishments such as the American Academy of Ophthalmology emphasize the importance of these cutting-edge approaches. According to the Food and Drug Administration's reports, over 10 new retinal drugs are anticipated to enter the market by 2030, further enhancing treatment capabilities and reinforcing market growth. ### **Increase in Diabetic Population** The prevalence of diabetes in the United States is on the rise, leading to an increased incidence of diabetic retinopathy, a serious retinal complication. The Centers for Disease Control and Prevention (CDC) reported that the number of adults diagnosed with diabetes is projected to reach 54.9 million by 2030, compared to 30.3 million in 2017. This substantial increase drives demand for effective retinal therapies, any often creating opportunities for pharmaceutical companies, like Eyepoint Pharmaceuticals and Ophthotech Corporation, to innovate and invest in developing targeted treatments. As diabetic retinopathy is a leading cause of vision impairment, the rising diabetes cases significantly impact the growth trajectory of the US Retinal Drugs Market Industry. ### **Enhanced Awareness and Screening Programs** There is an increasing awareness surrounding eye health and retinal diseases in the United States, significantly fueled by national campaigns and organizations like the American Diabetes Association and the American Academy of Ophthalmology. These campaigns encourage regular eye check-ups and screenings, resulting in earlier diagnosis and increased treatment rates for retinal diseases. Reports suggest that awareness programs have led to a 30% increase in preventative screenings over the past five years. This proactive approach not only enhances patient outcomes but also propels demand for retinal drugs, driving growth in the US Retinal Drugs Market Industry as more patients seek treatment for diagnosed conditions. ## **US Retinal Drugs Market Segment Insights** ### **Retinal Drugs Market Distribution Channel Insights** The Distribution Channel segment of the US Retinal Drugs Market plays a crucial role in ensuring the availability and accessibility of retinal drugs to healthcare providers and patients. This market is typically categorized into several channels including Hospital pharmacy, Retail pharmacy, and Online Pharmacy, each of which serves distinct needs and consumer behaviors. Hospital pharmacies generally cater to in-patient services, offering specialized care and immediate availability of critical medications, thereby forming a significant portion of the overall distribution landscape. The presence of trained pharmacists in these settings enhances medication guidance and management for complex retinal conditions, which are common in aging demographics. Retail pharmacies, on the other hand, represent a vital point of access for outpatients and those seeking easy access to medications. With the growing focus on patient-centric care, retail pharmacies are adapting by enhancing their services, offering consultations, and expanding their product offerings, thereby capturing a substantial market share. Online pharmacies have gained remarkable traction, especially in light of the shift towards digital health solutions. They provide convenience and privacy for patients, allowing easy access to retinal drugs while potentially lowering costs. The rise of telehealth also complements online pharmacies, enabling patients to consult with healthcare providers remotely before accessing their medications. Each of these channels contributes to the overall ecosystem of the US Retinal Drugs Market, addressing various consumer preferences and needs. Moreover, the increasing prevalence of retinal diseases, coupled with an aging population, is likely to further drive demand across all distribution channels. As healthcare continues to innovate and adapt, the integration of technology into these distribution methods, such as home delivery services from retail and online pharmacies, is likely to grow, enhancing the patient experience and improving medication adherence. Overall, while each distribution channel plays its role in the US Retinal Drugs Market, their collective contribution is pivotal in ensuring that patients receive effective treatment in a timely manner. Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review ### **Retinal Drugs Market Indication Insights** The US Retinal Drugs Market is primarily segmented by indication, including conditions such as macular degeneration, diabetic eye disease, and others. Macular degeneration remains a critical area of focus, as it is one of the leading causes of vision loss among older adults in the US, impacting millions each year. This segment reflects a substantial portion of the overall market, driven by the increasing prevalence of age-related eye diseases and the subsequent demand for effective treatment options. Similarly, diabetic eye disease consistently represents a significant challenge due to the rising rates of diabetes in the US, which affect vision health and necessitate ongoing medical intervention. Innovative therapies and advancements in treatment are vital to improving patient outcomes within this indication, leading to continued investment in Research and Development. Other conditions encompassed within this market segment also contribute to the overall landscape, showcasing an array of diverse retinal disorders that require specialized treatments. Overall, the US Retinal Drugs Market segmentation reveals a dynamic environment influenced by growing patient populations, ongoing medical needs, and technological advancements aimed at enhancing treatment effectiveness and accessibility. ## **US Retinal Drugs Market Key Players and Competitive Insights** The US Retinal Drugs Market is characterized by intense competition and rapid advancements in treatment options for retinal diseases such as diabetic retinopathy, age-related macular degeneration, and retinal vascular occlusions. This market is significantly driven by the increasing incidence of retinal disorders as well as the rising aging population, which is more susceptible to vision-threatening conditions. Competitive insights in this market reveal that companies are focusing on innovation, specifically the development of new formulations and delivery mechanisms. Partnerships, collaborations, and strategic alliances are prevalent as companies aim to enhance their product portfolios and market reach. The influence of regulatory frameworks and the push for more effective therapies also plays a crucial role in shaping competitive dynamics within the US market. ### **Key Company Analysis** #### **Genentech** Genentech has established a robust presence in the US Retinal Drugs Market, particularly noted for its strong research and development capabilities. The company’s commitment to innovation exemplifies its aim for leadership in the field of ophthalmology, where it provides advanced treatment options. Genentech's strengths lie in its well-renowned drug pipeline and a history of delivering meaningful therapies that address critical patient needs in retinal conditions. With its established network and strong brand reputation, Genentech leverages its expertise in biopharmaceuticals to maintain a competitive edge, driving both awareness and access to its treatments. The company also benefits from a strong focus on patient-centric solutions, which not only fulfills the therapeutic needs but also cultivates loyalty among healthcare providers and patients alike. #### **Aerie Pharmaceuticals** Aerie Pharmaceuticals specializes in developing therapies for the treatment of eye diseases, with a notable emphasis on retinal disorders. The company is well-positioned within the US Retinal Drugs Market, offering key products that address significant conditions affecting the retina. Aerie's strengths include its innovative approach to drug formulation and delivery systems, which have shown promising results in clinical trials. The company has engaged in strategic partnerships and acquisitions that bolster its market presence, allowing for enhanced research capabilities and broader distribution channels. Through its commitment to developing novel treatments, Aerie Pharmaceuticals continues to establish itself as a key player in the US market, catering to the evolving needs of patients while maintaining a focus on cutting-edge science and effective solutions. ### **Key Companies in the US Retinal Drugs Market Include** - Genentech - Aerie Pharmaceuticals - Novartis - Santen Pharmaceutical - Ocugen - Regeneron Pharmaceuticals - Pfizer - Eyenovia - **[Roche](https://www.roche.com/innovation/partnering/areas-of-interest/ophthalmology)** - Allergan - Acucela - Bayer - Lightpoint Medical - SuppreMol ## **US Retinal Drugs Market Industry Developments** Recent developments in the US Retinal Drugs Market highlight significant advancements and ongoing activities among key players. Genentech has made headlines with the successful expansion of its treatment portfolio, while Regeneron Pharmaceuticals showcased promising results from its ongoing Research and Development initiatives. In September 2023, Ocugen announced a partnership aimed at accelerating the development of its new therapies. Notably, Aerie Pharmaceuticals has been reinforcing its market presence through innovative projects aimed at providing next-generation treatments. The recent focus on mergers and acquisitions has also been notable; for instance, Novartis completed a strategic acquisition in August 2023 as part of its mission to enhance its treatment offerings. The market has experienced substantial growth over the past two to three years, bolstered by an increasing patient demographic requiring retinal care. Reports indicate that the market is expected to continue expanding driven by technological advancements and a greater emphasis on patient-centric healthcare solutions. As a result, companies such as Bayer and Allergan are poised to gain competitive advantages through their continued investments in novel retinal treatments and innovative solutions. This dynamic environment is reflective of the broader trends within the US healthcare landscape. ## **US Retinal Drugs Market Segmentation Insights** ### **Retinal Drugs Market Distribution Channel Outlook** - Hospital pharmacy - Retail pharmacy - Online Pharmacy ### **Retinal Drugs Market Indication Outlook** - Macular degeneration - Diabetic eye disease - Others ## Market Drivers ### Increased Focus on Personalized Medicine The shift towards personalized medicine is significantly influencing the retinal drugs market. Tailoring treatments to individual patient profiles enhances therapeutic outcomes and minimizes adverse effects. Genetic testing and biomarker identification are becoming integral in developing targeted therapies for retinal diseases. This trend is evident in the growing number of clinical trials focusing on personalized approaches, which are expected to yield innovative drugs in the coming years. The retinal drugs market may see a surge in demand as healthcare providers increasingly adopt personalized treatment plans, aligning with the broader movement towards precision medicine in the US healthcare system. ### Technological Advancements in Drug Delivery Systems Technological advancements in drug delivery systems are transforming the retinal drugs market. Innovations such as sustained-release implants and targeted delivery mechanisms enhance the efficacy of treatments for retinal diseases. For instance, the development of intravitreal injections has improved the bioavailability of drugs, allowing for lower dosages and reduced side effects. The retinal drugs market is projected to benefit from these advancements, as they enable more effective management of chronic conditions like diabetic macular edema. Additionally, the integration of digital health technologies, such as telemedicine and remote monitoring, may facilitate better patient adherence to treatment regimens, further driving market growth. ### Rising Healthcare Expenditure and Insurance Coverage Rising healthcare expenditure in the US is a crucial driver for the retinal drugs market. Increased spending on healthcare services and pharmaceuticals allows for greater access to advanced treatments for retinal diseases. Moreover, the expansion of insurance coverage for retinal therapies enhances patient access to necessary medications. According to the Centers for Medicare & Medicaid Services, national health expenditure is projected to grow at an average rate of 5.4% annually. This financial support is likely to facilitate the adoption of new retinal drugs, thereby propelling market growth. As more patients gain access to effective treatments, the retinal drugs market is expected to expand significantly. ### Aging Population and Rising Incidence of Eye Diseases In the US, the aging population is a primary driver of the retinal drugs market. As individuals age, the prevalence of age-related eye diseases, such as age-related macular degeneration (AMD) and diabetic retinopathy, increases significantly. According to the National Eye Institute, the number of Americans with AMD is projected to reach 3 million by 2025. This demographic shift necessitates the development and availability of effective retinal drugs, thereby expanding the market. Furthermore, the increasing incidence of diabetes, which is a major risk factor for retinal diseases, further compounds the demand for innovative treatments. The retinal drugs market is likely to experience substantial growth as healthcare providers seek to address these escalating health concerns. ### Growing Collaborations Between Pharmaceutical Companies and Research Institutions Collaborations between pharmaceutical companies and research institutions are fostering innovation in the retinal drugs market. These partnerships facilitate the sharing of resources, expertise, and technology, accelerating the development of new therapies. Joint ventures and research initiatives are increasingly common, as companies seek to leverage academic research to bring novel treatments to market. This trend is particularly relevant in the context of retinal diseases, where complex mechanisms require multidisciplinary approaches. The retinal drugs market is likely to benefit from these collaborations, as they enhance the pipeline of potential therapies and improve the overall landscape of treatment options available to patients. ## Future Outlook The [Retinal Drugs Market](https://www.marketresearchfuture.com/reports/retinal-drugs-market-11735) is projected to grow at a 6.3% CAGR from 2025 to 2035, driven by advancements in drug formulations, increasing prevalence of retinal diseases, and enhanced healthcare access. **New opportunities:** - Development of personalized medicine approaches for retinal diseases Expansion of telemedicine platforms for remote patient monitoring Investment in AI-driven diagnostic tools for early detection of retinal conditions By 2035, the retinal drugs market is expected to achieve substantial growth and innovation. ## Segment Insights ### By Distribution Channel: Retail Pharmacy (Largest) vs. Online Pharmacy (Fastest-Growing) In the US retinal drugs market, the distribution of market share predominantly favors Retail Pharmacy, reflecting consumer preference for accessibility and convenience. Retail pharmacies play a critical role in the supply chain, allowing patients to easily obtain their medications. Conversely, Online Pharmacy, while still smaller in share, is rapidly gaining traction as patients increasingly seek the convenience of home delivery, especially in the post-pandemic era. The growth of the Online Pharmacy segment is primarily driven by technological advancements and changing consumer behaviors, with a notable increase in digital health solutions. Enhanced online platforms providing easy access to retinal drugs have particularly appealed to younger consumers and those managing chronic eye conditions. Furthermore, ongoing investments in logistics and partnerships with pharmaceutical companies are set to bolster this emerging segment, encouraging more patients to transition towards online purchasing. Distribution Channel: Retail Pharmacy (Dominant) vs. Online Pharmacy (Emerging) Retail Pharmacy remains the dominant channel in the US retinal drugs market due to its extensive network and established customer trust. These pharmacies typically offer immediate access to medications and personalized consultations, enhancing patient compliance. In contrast, Online Pharmacy is an emerging channel, leveraging digital platforms to provide greater convenience and potentially lower costs for consumers. As more patients become accustomed to digital shopping, the Online Pharmacy segment is expected to grow significantly. Both channels serve vital roles, but while Retail Pharmacy offers traditional and trustworthy service, the Online segment aims to capture the growing demand for convenience and accessibility in healthcare. ### By Indication: Macular Degeneration (Largest) vs. Diabetic Eye Disease (Fastest-Growing) In the US retinal drugs market, Macular Degeneration holds the largest market share among the indications, dominating the landscape of treatment options available. This segment represents a significant portion of the overall market, outpacing others significantly, due to the high prevalence of age-related macular degeneration. Conversely, Diabetic Eye Disease has emerged as a critical area of focus, with increasing awareness and advancements in treatment protocols leading to its rapid growth in recent years. Growth trends for these indications show a clear distinction; while Macular Degeneration continues to benefit from an aging population and enhanced therapies, Diabetic Eye Disease is propelled by the rising incidence of diabetes and the urgent need for effective management solutions. Innovations in pharmacotherapy and surgical interventions are driving this growth further, making Diabetic Eye Disease the fastest-growing segment in the market, reflecting an evolving landscape in retinal drug development. Macular Degeneration (Dominant) vs. Diabetic Eye Disease (Emerging) Macular Degeneration remains the dominant indication in the US retinal drugs market, characterized by extensive patient outreach and a broad array of treatment options that cater to varying stages of the disease. This segment is heavily influenced by the aging population, resulting in sustained demand for innovative therapies. On the other hand, Diabetic Eye Disease is viewed as an emerging segment, driven by the alarming rise in diabetes prevalence and the consequent demand for effective treatments. This segment sees increasing investments in research and development, fostering a surge of new therapies aimed at managing complications associated with diabetic retinopathy, alongside a significant focus on preventive measures and patient education to mitigate disease progression. ## Competitive Benchmarking The retinal drugs market is characterized by a dynamic competitive landscape, driven by increasing prevalence of retinal diseases and a growing demand for innovative therapies. Key players such as Regeneron Pharmaceuticals (US), Novartis (CH), and Roche (CH) are at the forefront, each adopting distinct strategies to enhance their market presence. Regeneron Pharmaceuticals (US) focuses on innovation, particularly with its flagship product Eylea, which has seen expanded indications. Novartis (CH) emphasizes strategic partnerships, notably with digital health companies, to integrate technology into treatment pathways. Roche (CH) is investing heavily in research and development, aiming to introduce next-generation therapies that leverage gene therapy and personalized medicine, thereby shaping a competitive environment that prioritizes innovation and patient-centric solutions.The market structure appears moderately fragmented, with several players vying for market share. Key business tactics include localizing manufacturing to reduce costs and optimize supply chains, which is crucial in maintaining competitive pricing. The collective influence of these major companies fosters a competitive atmosphere where agility and responsiveness to market needs are paramount. This fragmentation allows for niche players to emerge, potentially disrupting established norms through specialized offerings. In October Regeneron Pharmaceuticals (US) announced a collaboration with a leading AI firm to enhance patient monitoring and treatment adherence for Eylea. This strategic move underscores the importance of integrating technology into therapeutic frameworks, potentially improving patient outcomes and operational efficiencies. By leveraging AI, Regeneron aims to refine its approach to patient care, which could set a new standard in the retinal drugs market. In September Novartis (CH) launched a new digital platform aimed at streamlining the patient journey for those undergoing treatment for retinal diseases. This initiative reflects a broader trend towards digital transformation in healthcare, suggesting that Novartis is keen on enhancing patient engagement and satisfaction. Such a platform may not only improve treatment adherence but also provide valuable data for future product development. In August Roche (CH) received FDA approval for a novel gene therapy targeting a rare retinal condition, marking a significant advancement in its product pipeline. This approval is indicative of Roche's commitment to pioneering innovative therapies that address unmet medical needs. The introduction of gene therapy could potentially revolutionize treatment paradigms, positioning Roche as a leader in the retinal drugs market. As of November current competitive trends are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence into healthcare solutions. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in enhancing their technological capabilities. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on innovation, technological advancements, and supply chain reliability. This shift may redefine market dynamics, compelling companies to invest in cutting-edge solutions that not only meet regulatory standards but also enhance patient outcomes. ## Recent News & Developments Recent developments in the US Retinal Drugs Market highlight significant advancements and ongoing activities among key players. Genentech has made headlines with the successful expansion of its treatment portfolio, while Regeneron Pharmaceuticals showcased promising results from its ongoing Research and Development initiatives. In September 2023, Ocugen announced a partnership aimed at accelerating the development of its new therapies. Notably, Aerie Pharmaceuticals has been reinforcing its market presence through innovative projects aimed at providing next-generation treatments. The recent focus on mergers and acquisitions has also been notable; for instance, Novartis completed a strategic acquisition in August 2023 as part of its mission to enhance its treatment offerings. The market has experienced substantial growth over the past two to three years, bolstered by an increasing patient demographic requiring retinal care. Reports indicate that the market is expected to continue expanding driven by technological advancements and a greater emphasis on patient-centric healthcare solutions. As a result, companies such as Bayer and Allergan are poised to gain competitive advantages through their continued investments in novel retinal treatments and innovative solutions. This dynamic environment is reflective of the broader trends within the US healthcare landscape. ## Report Scope | MARKET SIZE 2024 | 1402.65(USD Million) | | --- | --- | | MARKET SIZE 2025 | 1491.02(USD Million) | | MARKET SIZE 2035 | 2747.29(USD Million) | | COMPOUND ANNUAL GROWTH RATE (CAGR) | 6.3% (2025 - 2035) | | REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends | | BASE YEAR | 2024 | | Market Forecast Period | 2025 - 2035 | | Historical Data | 2019 - 2024 | | Market Forecast Units | USD Million | | Key Companies Profiled | Regeneron Pharmaceuticals (US), Novartis (CH), Roche (CH), Bayer (DE), Pfizer (US), Santen Pharmaceutical (JP), Horizon Therapeutics (IE), Apellis Pharmaceuticals (US), Alimera Sciences (US) | | Segments Covered | Distribution Channel, Indication | | Key Market Opportunities | Advancements in gene therapy and personalized medicine enhance treatment options in the retinal drugs market. | | Key Market Dynamics | Rising demand for innovative retinal therapies drives competitive dynamics and regulatory adaptations in the market. | | Countries Covered | US | ## Frequently Asked Questions **Q: What was the overall market valuation of the US retinal drugs market in 2024?** A: The overall market valuation was $1402.65 Million in 2024. **Q: What is the projected market valuation for the US retinal drugs market by 2035?** A: The projected market valuation for 2035 is $2747.29 Million. **Q: What is the expected CAGR for the US retinal drugs market during the forecast period 2025 - 2035?** A: The expected CAGR for the market during 2025 - 2035 is 6.3%. **Q: Which companies are considered key players in the US retinal drugs market?** A: Key players include Regeneron Pharmaceuticals, Novartis, Roche, Bayer, Pfizer, Santen Pharmaceutical, Horizon Therapeutics, Apellis Pharmaceuticals, and Alimera Sciences. **Q: What were the segment valuations for the distribution channels in the US retinal drugs market?** A: In 2024, Hospital Pharmacy was valued at $420.79 Million, Retail Pharmacy at $560.52 Million, and Online Pharmacy at $421.34 Million. **Q: How does the market perform in terms of indications for retinal drugs?** A: For indications, Macular Degeneration was valued at $700.0 Million, Diabetic Eye Disease at $500.0 Million, and Others at $202.65 Million in 2024. **Q: What is the significance of the Hospital Pharmacy segment in the US retinal drugs market?** A: The Hospital Pharmacy segment had a valuation of $420.79 Million in 2024, indicating its crucial role in the market. **Q: How does the Retail Pharmacy segment compare to other distribution channels?** A: The Retail Pharmacy segment was valued at $560.52 Million in 2024, making it one of the largest distribution channels. **Q: What is the growth outlook for the US retinal drugs market?** A: The market is expected to grow significantly, reaching $2747.29 Million by 2035, driven by a CAGR of 6.3%. **Q: What are the implications of the projected growth for key players in the market?** A: The projected growth may present opportunities for key players like Regeneron and Novartis to expand their market share and innovate. --- *This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/us-retinal-drugs-market-19712*